Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 0 25 versus TIROSINT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 0 25 versus TIROSINT.
THYROLAR-0.25 vs TIROSINT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyroid hormone (liothyronine, L-triiodothyronine or T3) binds to thyroid hormone receptors in the nucleus, altering gene transcription and protein synthesis, leading to increased metabolic rate, oxygen consumption, and thermogenesis.
Tirosint is a synthetic form of levothyroxine (T4), which is converted to triiodothyronine (T3) in peripheral tissues. T3 binds to thyroid hormone receptors in the nucleus, modulating gene transcription to increase metabolic rate, protein synthesis, and oxygen consumption.
Oral, 0.25 mg (1 tablet) once daily; adjust based on TSH response.
Initial dose 1.6 mcg/kg orally once daily, adjusted based on TSH levels. Typical maintenance dose 50-200 mcg/day.
None Documented
None Documented
Levothyroxine (T4): ~7 days; liothyronine (T3): ~1 day. Clinical context: Steady-state achieved in ~5 weeks for T4; T3 half-life shorter leads to more frequent dosing if used alone.
Terminal half-life approximately 7 days in euthyroid individuals; prolonged in hypothyroidism (up to 9-10 days) and shortened in hyperthyroidism (3-4 days). Clinical context: steady-state reached in 4-6 weeks; dosage adjustments require 6-8 weeks for full effect.
Renal: ~40% as conjugated metabolites (glucuronides and sulfates); fecal: ~20% via bile; minor biliary elimination of parent drug (<5%). Total renal clearance of iodine: ~30%.
Renal (approximately 30-40% as unchanged drug and metabolites, primarily glucuronide and sulfate conjugates); fecal (approximately 20-30% via bile); total clearance is low (~0.05 L/hr/kg).
Category C
Category C
Thyroid Hormone
Thyroid Hormone